Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Cash: 2013-2024

Historic Change in Cash for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$121.9 million.

  • ImmunityBio's Change in Cash fell 323.45% to -$76.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 22.78%. This contributed to the annual value of -$121.9 million for FY2024, which is 175.78% down from last year.
  • Per ImmunityBio's latest filing, its Change in Cash stood at -$121.9 million for FY2024, which was down 175.78% from $160.8 million recorded in FY2023.
  • ImmunityBio's Change in Cash's 5-year high stood at $160.8 million during FY2023, with a 5-year trough of -$121.9 million in FY2024.
  • In the last 3 years, ImmunityBio's Change in Cash had a median value of -$76.3 million in 2022 and averaged -$12.5 million.
  • In the last 5 years, ImmunityBio's Change in Cash soared by 457.55% in 2021 and then crashed by 175.78% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Change in Cash stood at -$40.9 million in 2020, then skyrocketed by 457.55% to $146.2 million in 2021, then plummeted by 152.20% to -$76.3 million in 2022, then skyrocketed by 310.73% to $160.8 million in 2023, then slumped by 175.78% to -$121.9 million in 2024.